Literature DB >> 7939753

Bone metastases: improving the therapeutic index.

H I Scher1, L W Chung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7939753

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  13 in total

1.  Subchondral metastasis: report of five cases.

Authors:  J J Peterson; T A Manning; J J Callaghan; G Y El-Khoury
Journal:  Iowa Orthop J       Date:  1999

Review 2.  Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Authors:  Michael J Morris; Neeta Pandit-Taskar; Chaitanya Divgi; Steven Larson; Howard I Scher
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

3.  Bisphosphonates in metastatic prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2003

4.  Three-dimensional trabecular bone architecture of the lumbar spine in bone metastasis from prostate cancer: comparison with degenerative sclerosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Shigeki Imai; Yasumasa Kajihara; Masao Fukunaga
Journal:  Skeletal Radiol       Date:  2004-11-16       Impact factor: 2.199

5.  A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.

Authors:  Franklin M Chu; Joel Picus; Paula M Fracasso; Robert Dreicer; Zhihui Lang; Brenda Foster
Journal:  Invest New Drugs       Date:  2010-02-11       Impact factor: 3.850

Review 6.  Targeting bone metastases in prostate cancer: improving clinical outcome.

Authors:  Jean-Jacques Body; Sandra Casimiro; Luís Costa
Journal:  Nat Rev Urol       Date:  2015-05-05       Impact factor: 14.432

7.  Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

Authors:  Joel B Nelson; William Love; Joseph L Chin; Fred Saad; Claude C Schulman; Darryl J Sleep; Jiang Qian; Joyce Steinberg; Michael Carducci
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

8.  The use of zoledronic acid in Japanese men with stage D2 prostate cancer.

Authors:  Kogenta Nakamura; Yoshiaki Yamada; Charles J Rosser; Maki Arakawa; Kenji Zennmai; Yoshiharu Kato; Masahito Watanabe; Remi Katsuda; Motoi Tobiume; Katsuya Naruse; Shigeyuki Aoki; Tomohiro Taki; Hiroko Saito; Takaaki Hasegawa; Nobuaki Honda
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 9.  Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting.

Authors:  Arich Ryan Reynolds; Natasha Kyprianou
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 10.  Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?

Authors:  Alessandra Modena; Francesco Massari; Chiara Ciccarese; Matteo Brunelli; Matteo Santoni; Rodolfo Montironi; Guido Martignoni; Giampaolo Tortora
Journal:  Target Oncol       Date:  2016-08       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.